These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25641750)

  • 1. Characterization of the interaction of the novel antihypertensive etamicastat with human dopamine-β-hydroxylase: comparison with nepicastat.
    Bonifácio MJ; Sousa F; Neves M; Palma N; Igreja B; Pires NM; Wright LC; Soares-da-Silva P
    Eur J Pharmacol; 2015 Mar; 751():50-8. PubMed ID: 25641750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat.
    Loureiro AI; Bonifácio MJ; Fernandes-Lopes C; Pires N; Igreja B; Wright LC; Soares-da-Silva P
    Xenobiotica; 2015; 45(9):828-39. PubMed ID: 25915108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
    Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
    Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etamicastat, a new dopamine-ß-hydroxylase inhibitor, pharmacodynamics and metabolism in rat.
    Loureiro AI; Bonifácio MJ; Fernandes-Lopes C; Igreja B; Wright LC; Soares-da-Silva P
    Eur J Pharmacol; 2014 Oct; 740():285-94. PubMed ID: 25058908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase.
    Stanley WC; Li B; Bonhaus DW; Johnson LG; Lee K; Porter S; Walker K; Martinez G; Eglen RM; Whiting RL; Hegde SS
    Br J Pharmacol; 1997 Aug; 121(8):1803-9. PubMed ID: 9283721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood pressure decrease in spontaneously hypertensive rats folowing renal denervation or dopamine β-hydroxylase inhibition with etamicastat.
    Pires NM; Igreja B; Moura E; Wright LC; Serrão MP; Soares-da-Silva P
    Hypertens Res; 2015 Sep; 38(9):605-12. PubMed ID: 25854989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained high blood pressure reduction with etamicastat, a peripheral selective dopamine β-hydroxylase inhibitor.
    Igreja B; Wright LC; Soares-da-Silva P
    J Am Soc Hypertens; 2016 Mar; 10(3):207-16. PubMed ID: 26803288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-acetylation of etamicastat, a reversible dopamine-β-hydroxylase inhibitor.
    Loureiro AI; Fernandes-Lopes C; Bonifácio MJ; Wright LC; Soares-da-Silva P
    Drug Metab Dispos; 2013 Dec; 41(12):2081-6. PubMed ID: 24013186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of dopamine-beta-hydroxylase enhances dopamine release from noradrenergic terminals in the medial prefrontal cortex.
    Devoto P; Flore G; Saba P; Frau R; Gessa GL
    Brain Behav; 2015 Oct; 5(10):e00393. PubMed ID: 26516613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular effects of nepicastat (RS-25560-197), a novel dopamine beta-hydroxylase inhibitor.
    Stanley WC; Lee K; Johnson LG; Whiting RL; Eglen RM; Hegde SS
    J Cardiovasc Pharmacol; 1998 Jun; 31(6):963-70. PubMed ID: 9641484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dopamine β-hydroxylase inhibitor, nepicastat, suppresses chocolate self-administration and reinstatement of chocolate seeking in rats.
    Zaru A; Maccioni P; Colombo G; Gessa GL
    Br J Nutr; 2013 Oct; 110(8):1524-33. PubMed ID: 23561307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of novel, peripherally selective chromanyl imidazolethione-based inhibitors of dopamine beta-hydroxylase.
    Beliaev A; Learmonth DA; Soares-da-Silva P
    J Med Chem; 2006 Feb; 49(3):1191-7. PubMed ID: 16451083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etamicastat, a novel dopamine β-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension.
    Almeida L; Nunes T; Costa R; Rocha JF; Vaz-da-Silva M; Soares-da-Silva P
    Clin Ther; 2013 Dec; 35(12):1983-96. PubMed ID: 24296323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further characterization of the cardiovascular effects of the dopamine beta-hydroxylase inhibitor SK&F 102698 in conscious hypertensive rats.
    Ohlstein EH; Kruse LI; Ezekiel M; Willette RN
    J Pharmacol Exp Ther; 1988 Oct; 247(1):186-95. PubMed ID: 3050029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of nepicastat upon dopamine-β-hydroxylase activity and dopamine and norepinephrine levels in the rat left ventricle, kidney, and adrenal gland.
    Catelas DN; Serrão MP; Soares-Da-Silva P
    Clin Exp Hypertens; 2020; 42(2):118-125. PubMed ID: 30821508
    [No Abstract]   [Full Text] [Related]  

  • 16. Human disposition, metabolism and excretion of etamicastat, a reversible, peripherally selective dopamine β-hydroxylase inhibitor.
    Loureiro AI; Rocha JF; Fernandes-Lopes C; Nunes T; Wright LC; Almeida L; Soares-da-Silva P
    Br J Clin Pharmacol; 2014 Jun; 77(6):1017-26. PubMed ID: 24168152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dopamine β-hydroxylase inhibitor, nepicastat, reduces different alcohol-related behaviors in rats.
    Colombo G; Maccioni P; Vargiolu D; Loi B; Lobina C; Zaru A; Carai MA; Gessa GL
    Alcohol Clin Exp Res; 2014 Sep; 38(9):2345-53. PubMed ID: 25257286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular effects of a new potent dopamine beta-hydroxylase inhibitor in spontaneously hypertensive rats.
    Ohlstein EH; Kruse LI; Ezekiel M; Sherman SS; Erickson R; DeWolf WE; Berkowitz BA
    J Pharmacol Exp Ther; 1987 May; 241(2):554-9. PubMed ID: 3572812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-(Thienylalkyl)imidazole-2(3H)-thiones as potent competitive inhibitors of dopamine beta-hydroxylase.
    McCarthy JR; Matthews DP; Broersma RJ; McDermott RD; Kastner PR; Hornsperger JM; Demeter DA; Weintraub HJ; Whitten JP
    J Med Chem; 1990 Jul; 33(7):1866-73. PubMed ID: 2362264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular safety pharmacology profile of etamicastat, a novel peripheral selective dopamine-β-hydroxylase inhibitor.
    Pires NM; Loureiro AI; Igreja B; Lacroix P; Soares-da-Silva P
    Eur J Pharmacol; 2015 Mar; 750():98-107. PubMed ID: 25641747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.